Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

Status: RECRUITING

Eligibility Criteria

Age: 6 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

* All genders ≥ 6 years of age at Visit 1 * Documentation of a CF diagnosis * Clinician intent to treat index CF PEx with a planned 14-day course of IV antimicrobials * At least one documented Pa positive culture within two years prior to Visit 1

Exclusion Criteria:

* Participant is not pregnant * No known renal impairment or history of solid organ transplantation * No IV antimicrobial treatment, ICU admission, pneumothorax, or hemoptysis within 6 weeks prior to Visit 1 * No use of investigational therapies, new CF transmembrane conductance regulator (CFTR) modulators, or treatment for Nontuberculous mycobacteria (NTM) within 4 weeks prior to Visit 1 * No history of hypersensitivity, vestibular, or auditory toxicity with aminoglycosides * No more than one day of IV aminoglycosides administered for the current PEx treatment prior to Visit 1

Conditions & Interventions

Interventions:
DRUG: Beta-lactam antibiotic, DRUG: Aminoglycoside
Conditions:
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Keywords:
Cystic Fibrosis, CF, Cystic Fibrosis Pulmonary Exacerbation, aminoglycoside, beta-lactam, β-lactam, STOP, STOP360

More Information

Contact(s): Rachael Buckingham, BS - Rachael.buckingham@seattlechildrens.org
Principal Investigator:
Phase: PHASE4
IRB
Number:
System ID: NCT05548283
